Hemic and Lymphatic Diseases: Clinical Trials

13879 completed, 3951 recruiting, 3923 unknown, 3116 terminated. 10389 Phase 2, 7200 Phase 1, 3978 Not applicable, 3270 Phase 3, 1110 Phase 4.

By phase and status

Phase	Trials	Status
Phase 2	10389	Completed 4670, Terminated 1482, Recruiting 1372, Unknown 1139, Active not recruiting 795, Withdrawn 478, Not yet recruiting 383, Suspended 41, Enrolling by invitation 29
Phase 1	7200	Completed 3248, Terminated 1147, Recruiting 976, Unknown 676, Active not recruiting 505, Withdrawn 355, Not yet recruiting 226, Suspended 52, Enrolling by invitation 15
Not applicable	3978	Completed 1884, Unknown 644, Recruiting 591, Not yet recruiting 257, Terminated 249, Active not recruiting 173, Withdrawn 133, Enrolling by invitation 35, Suspended 12
Phase 3	3270	Completed 1717, Unknown 406, Recruiting 354, Terminated 336, Active not recruiting 250, Not yet recruiting 103, Withdrawn 86, Enrolling by invitation 10, Suspended 8
Phase 4	1110	Completed 557, Unknown 238, Terminated 97, Recruiting 95, Not yet recruiting 46, Withdrawn 46, Active not recruiting 26, Enrolling by invitation 4, Suspended 1
Early Phase 1	465	Recruiting 107, Unknown 102, Completed 101, Not yet recruiting 59, Terminated 46, Active not recruiting 22, Withdrawn 20, Suspended 6, Enrolling by invitation 2

Follow this condition Literature Review of Hemic and Lymphatic Diseases trials Research Report on Hemic and Lymphatic Diseases

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
FLASH Pilot Phase 1 Safety Study IntraOp Mobetron UHDR, Linac - Cutaneous Lymphoma	Not applicable	Not yet recruiting	Lesley A. Jarvis	10	2029-10-31	2026-05-27
A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Lymphoblastic Leukaemia Blinatumomab, HyperCVAD - Philadelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic Leukemia	Phase 3	Not yet recruiting	Amgen	560	2028-06-30	2026-09-15
Pyronaridine in Acute Myeloid Leukemia (AML) Pyronaridine Tetraphosphate - Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL)	Phase 2	Suspended	Armaceutica, Inc.	200	2028-02-21	2026-10-19
Effect of Ginger on Heavy Menstrual Bleeding in Women With Coagulation Disorders Ginger, Placebo - Women With Coagulation Disorders	Early Phase 1	Not yet recruiting	University of Valladolid	74	2028-02-01	2026-05-19
MM-CARE: Cardiovascular Risk Assessment in Adults With Multiple Myeloma Oncology-Embedded Cardiovascular Risk Assessment Pathway, Primary Care Provider-Directed Cardiovascular Risk Assessment Pathway - Multiple Myeloma, Heart Disease Risk Factors	Not applicable	Not yet recruiting	University of Vermont Medical Center	33	2028-02-01	2026-08-25
Genetic Ablation of CD33 in HSC to Broaden the Therapeutic Index of CD33-directed Immunotherapy in Patients with AML Donor-derived CD34+ HSC with CRISPR/Cas9-mediated CD33 deletion, Gemtuzumab Ozogamicin - Relapsed/Refractory Acute Myeloid Leukemia (AML)	Phase 1	Not yet recruiting	German Cancer Research Center	12	2028-01-01	2025-03-14
OPTIMAL LEAP: Optimizing Dihydroartemisinin-Piperaquine IPTsc Intervals to Advance Learning, Executive Function, Attendance, and Antimalarial Resistance Surveillance in Kenyan Schoolchildren Monthly DP, Quarterly DP - Malaria, Asymptomatic Malaria	Phase 3	Not yet recruiting	Indiana University	1500	2028-01-01	2026-09-01
Methadone as an Alternative Treatment for Children Underdoing HSCT PCA plus methadone (Experimental), PCA Alone (SOC) - Leukemia, Aplastic Anemia	Phase 3	Suspended	University of Texas Southwestern Medical Center	60	2028-01-01	2025-10-23
Prenatal Transplantation for Fetuses With Fanconi Anemia IUHSCT for FA-affected fetuses - Fanconi Anemia, Anemia, Hypoplastic, Congenital	Phase 1 / Phase 2	Not yet recruiting	Agnieszka Czechowicz	12	2028-01-01	2026-06-16
A Phase 1 Open-Label, Dose-Ranging Safety and Pharmacokinetics Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML) Cytarabine, Oral Cladribine - Acute Myeloid Leukemia (AML)	Phase 1 / Phase 2	Not yet recruiting	M.D. Anderson Cancer Center	58	2027-12-01	2026-08-25
Study of NM8074 in Patients With aHUS With Evidence of Ongoing Thrombotic Microangiopathy NM8074 - aHUS - Atypical Hemolytic Uremic Syndrome	Phase 2	Not yet recruiting	NovelMed Therapeutics	12	2027-11-01	2026-04-13
Self-administered Acupressure in Patients With Sickle Cell Disease Verum Acupressure (using AcuWand), Sham Acupressure (using AcuWand) - Sickle Cell Disease (SCD)	Not applicable	Not yet recruiting	University of Cincinnati	300	2027-10-01	2026-10-15
The Feasibility and Effects of Exercise on Patients Suffering From Multiple Myeloma Individual Exercise, Group Exercise - Multiple Myeloma	Not applicable	Suspended	Medical University of Vienna	45	2027-09-01	2026-10-09
Development of a Provider-Focused Intervention to Improve Health Outcomes in Pediatric Sickle Cell Disease Individuation and Perspective-Taking (IPT), pediatric SCD pain management education session - Sickle Cell Disease, Sickle Cell Anemia in Children	Not applicable	Not yet recruiting	Connecticut Children's Medical Center	30	2027-09-01	2026-04-29
Family-Focused Study to Support Medication for Opioid Use Disorder FamilyCHESS, Standard of Care - Opioid Use Disorder, Opioid Use Disorder, Moderate	Not applicable	Not yet recruiting	University of Wisconsin, Madison	338	2027-08-31	2026-07-07
Zanubrutinib and Sonrotoclax for the Treatment of Relapsed Chronic Lymphocytic Leukemia /Small Lymphocytic Leukemia, ZeuS-2 Trial Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	Phase 2	Not yet recruiting	City of Hope Medical Center	44	2027-08-04	2026-09-10
Phase IIb Multicenter Randomized Controlled Trial Evaluating the Efficacy of Sivelestat in Patients With Septic Coagulopathy • Sivelestat intravenous infusion, NaCl intravenous infusion - Septic Shock, Coagulopathy	Phase 2	Not yet recruiting	University Hospital, Strasbourg, France	120	2027-08-01	2026-08-20
Astragalus for Symptomatic Alleviation in High-grade Lymphoma Astragalus, Placebo - High-grade Lymphoma	Phase 3	Not yet recruiting	Bnai Zion Medical Center	60	2027-08-01	2026-09-30
Conditioning Regimen Containing Low-Dose ATG for the Treatment of AA Receiving sUCBT Anti-Thymocyte Globulin (Rabbit) (Thymoglobulin®) - Aplastic Anaemia	Phase 2	Not yet recruiting	Anhui Provincial Hospital	59	2027-08-01	2026-10-21
Evaluation of Efficacy and Safety of a Single Dose of Exa-cel in Participants With Severe Sickle Cell Disease, βS/ βC Genotype Exa-cel - Sickle Cell Disease	Phase 3	Withdrawn	Vertex Pharmaceuticals Incorporated		2027-07-31	2026-03-25

Showing 20 of 29453. Sign in to see all of them.

Narrower conditions

Multiple Myeloma (3658)  ·  Leukemia, Myeloid, Acute (3581)  ·  Lymphoma (3015)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (2519)  ·  Leukemia (2378)  ·  Lymphoma, Non-Hodgkin (2287)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (2018)  ·  Myelodysplastic Syndromes (1966)  ·  Lymphoma, Follicular (1873)  ·  Lymphoma, Large B-Cell, Diffuse (1824)  ·  Anemia (1665)  ·  Hematologic Neoplasms (1435)  ·  Recurrence (1428)  ·  Hodgkin Disease (1301)  ·  Lymphoma, Mantle-Cell (1209)

Broader conditions

Hematologic Diseases (21618)  ·  Neoplasms (18701)  ·  Neoplasms by Histologic Type (17974)  ·  Immune System Diseases (15848)  ·  Lymphoproliferative Disorders (14119)  ·  Immunoproliferative Disorders (13996)  ·  Lymphatic Diseases (12699)  ·  Pathological Conditions, Signs and Symptoms (7872)  ·  Pathologic Processes (7160)  ·  Leukemia (6399)  ·  Hemorrhagic Disorders (6327)  ·  Cardiovascular Diseases (5415)  ·  Lymphoma (5265)  ·  Vascular Diseases (5214)

Interventions

Cyclophosphamide (1919)  ·  Rituximab (1535)  ·  Dexamethasone (1346)  ·  Cytarabine (1141)  ·  Lenalidomide (893)  ·  fludarabine (857)  ·  Vincristine (728)  ·  Bortezomib (695)  ·  Etoposide (689)  ·  Doxorubicin (659)  ·  Prednisone (655)  ·  fludarabine phosphate (628)  ·  venetoclax (627)  ·  Azacitidine (610)  ·  Methotrexate (587)

Sponsors

M.D. Anderson Cancer Center (838)  ·  National Cancer Institute (NCI) (826)  ·  Novartis Pharmaceuticals (416)  ·  Memorial Sloan Kettering Cancer Center (353)  ·  Hoffmann-La Roche (287)  ·  Assistance Publique - Hôpitaux de Paris (277)  ·  Institute of Hematology & Blood Diseases Hospital, China (277)  ·  Fred Hutchinson Cancer Center (271)  ·  Celgene (236)  ·  Mayo Clinic (233)  ·  National Heart, Lung, and Blood Institute (NHLBI) (225)  ·  City of Hope Medical Center (219)  ·  Pfizer (211)  ·  GlaxoSmithKline (204)  ·  St. Jude Children's Research Hospital (201)

Countries

United States (13804)  ·  China (3726)  ·  France (3138)  ·  Italy (2410)  ·  Germany (2200)  ·  United Kingdom (2054)  ·  Spain (1961)  ·  Canada (1934)  ·  Australia (1327)  ·  South Korea (1067)  ·  Belgium (1060)  ·  Netherlands (1017)  ·  Poland (972)  ·  Japan (857)  ·  Israel (795)

Results publications

PMID 34515338, PMID 36005278, PMID 41671463, PMID 36791280, PMID 32499241, PMID 41114449, PMID 35622074, PMID 34932836, PMID 40135712, PMID 32632956, PMID 26965694, PMID 37975597, PMID 33783815, PMID 34398557, PMID 36240296, PMID 38780066, PMID 31401903, PMID 33394722, PMID 40550489, PMID 19005182, PMID 24383844, PMID 25527568, PMID 33242441, PMID 33357481, PMID 38502198, PMID 39319495, PMID 39563886, PMID 40750723, PMID 23524640, PMID 26373676, PMID 29674506, PMID 30957581, PMID 31221778, PMID 31375516, PMID 34724566, PMID 34922648, PMID 35235189, PMID 35244208, PMID 35829925, PMID 36064577, PMID 36184192, PMID 37022569, PMID 37192741, PMID 37254256, PMID 37505794, PMID 38620092, PMID 22689675, PMID 23065508, PMID 23620574, PMID 27209293

NIH funding

2023 (278), 2017 (151), 2016 (149), 2015 (143), 2018 (143), P30CA033572 (142), 2014 (140), 2019 (122), P30CA015704 (121), 2009 (101), 2025 (97), P30CA015083 (92), U10CA032102 (88), 2008 (74), P30CA016672 (73)